Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases. We are developing vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) with a New Drug Application under review by the FDA for the treatment of Erosive GERD and a late-stage development program in Non-Erosive GERD. Vonoprazan-based regimens are approved in the U.S. as part of a co-packaged product in combination with antibiotics for the treatment of H. pylori infection in adults, marketed as VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK® (vonoprazan, amoxicillin).
We are a growing team of highly driven professionals who are passionate in our mission to improve the lives of people suffering from GI diseases. Phathom has built a unique culture that embraces entrepreneurship, fosters collective ownership and accountability, and celebrates personal and professional achievement. We are looking for dynamic, self-motivated, and purpose-driven team players who embody our core values and are excited by the idea of working in a fast-paced environment to help us transform the GI treatment landscape.